PCT operates cell culture processing facilities in California and New Jersey which custom-cultivate and process cells for regenerative medicine, cancer and immune cell therapy. Hitachi Chemical, a subsidiary of Hitachi Kasei, had acquired 19,9 % of all PCT shares in March 2016 and entered into collaborative agreements. At this time, Hitachi Chemical has signed a contract to acquire the remaining shares (80.1%) of the PCT company owned by Caladrius for about 75 million dollars (about 8.7 billion yen), and PCT will be a wholly owned subsidiary of Hitachi Chemical Company. The acquisition is completed in May 2017.
Hitachi Chemical news release, March 17, 2017